Hormone Receptor-Positive Advanced Breast Cancer Introduction

Slides:



Advertisements
Similar presentations
SABCS 2011 BOLERO-2 Updated Results
Advertisements

Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
1Bachelot T et al. Proc SABCS 2010;Abstract S1-6.
ESMO 2011 Breast Cancer BOLERO-2 Authors: CARE Faculty (Drs. Anil Joy and Sunil Verma) Date posted: October 12, 2011.
Targeting endocrine-resistance pathways in breast cancer
© MediPaper 2016 ASCO 2016 Palbociclib (Ibrance™) Data MediPaper Study / AbstractPhIndicationLineNN BiomarkerMethodologyArms1 o EPORRCBRDCRmPF S (Mo) PFS.
Cyclin Kinases inhibitors and beyond
MONARCH 2: Phase III Study of Abemaciclib + Fulvestrant in HR+/HER2- Advanced Breast Cancer After Progression on Endocrine Therapy CCO Independent Conference.
¿Qué ver en ASCO 2017?.
CCO Independent Conference Coverage
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
New Insights in the Hormone Therapy for Breast Cancer
PALOMA-2: Addition of Palbociclib to Frontline Letrozole Significantly Improves PFS in Postmenopausal ER+/HER2- Advanced Breast Cancer CCO Independent.
PHEREXA: Survival Data
CCO Independent Conference Coverage
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Endocrine Therapy for Metastatic Breast Cancer
Optimizing Combination Endocrine Therapy in HR-Positive Advanced Breast Cancer.
Presented By Luca Malorni at 2017 ASCO Annual Meeting
SAFETY AND EFFICACY OF EVEROLIMUS PLUS EXEMESTANE IN METASTATIC BREAST CANCER BEYOND THE SECOND LINE TREATMENT: A SINGLE INSTITUTION EXPERIENCE M. Giampaglia,
Endocrine Combinations in HR-Positive MBC: The Future Is Now
Evolving Paradigms in Recurrent/Metastatic SCCHN
Evolving Paradigms in the Management of HR-Positive Breast Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: Implementing Paradigms in Clinical Practice.
The Nurse View: Hormone Receptor-Positive Advanced Breast Cancer
Expanding Horizons in the Clinical Care of ER-Positive, HER2-Negative Metastatic Breast Cancer.
Improving Survival in Glioblastoma Multiforme
HR positive, Her-2 negative MBC
Advanced NSCLC Without Actionable Mutations
Updates on the Use of Adjuvant Therapy in HER2-Positive Breast Cancer
New Horizons in the Management of Advanced Breast Cancer
CDK 4 and 6 Inhibitors in HR-Positive Breast Cancer: A Clinical Update
Overall Program Goals. Overall Program Goals Current Approaches.
Individualizing Treatment Options in Advanced ER-Positive Breast Cancer.
Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.
Navigating New Treatment Landscapes in HR-Positive, HER2-Negative Metastatic Breast Cancer.
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
Moving Evidence into Practice: Breast Cancer Highlights From Chicago
Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.
CDK4/6 Inhibitors in Breast Cancer:
CDK 4 and 6 Inhibitors in HR-Positive Advanced Breast Cancer: Assessing New Data.
CDK4/6 Inhibitors in Practice
Managing gBRCA-Positive Metastatic Breast Cancer
Treating mRCC After Initial Antiangiogenic Therapy:
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
Using CDK4/6 Inhibitors to Manage HR-Positive Metastatic Breast Cancer
Treatment of HR+ Breast Cancer: A Clinical Update
Program Goals. Single vs Dual HER2 Blockade for Metastatic HER2-Positive Breast Cancer.
Hormone Receptor-Positive Advanced Breast Cancer:
Vincenzo Adamo Luminal Metastatic Breast Cancer:
Breast Cancer Statistics
CDK4/6 Biomarkers: Issues and Opportunities
The Road to Quality Improvement in HER2-Positive Breast Cancer
Introduction Advanced Hormone Receptor-Positive Breast Cancer
Treatment of Locally Advanced Pancreatic Cancer
Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
New Paradigms in HR-Positive Advanced Breast Cancer
Optimizing Treatment in HR-Positive Breast Cancer: A Case-Based Discussion.
Practical Guidance on the Management of Pan-Negative NSCLC
CDK 4/6 Inhibitors in Breast Cancer
Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.
Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.
Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.
Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer
CDK4/6 Inhibitors.
Taking a Closer Look at Recurrent/Metastatic SCCHN
Real-World Evidence.
DISSECTING THE DECISION
Miquel Àngel Seguí Palmer ¿Ciclinas para todas?
Presentation transcript:

Finding the Right Option: Hormone Receptor-Positive Advanced Breast Cancer

Hormone Receptor-Positive Advanced Breast Cancer Introduction

Case Study 1

Case Study 1 (cont)

Response to Therapy

ASCO Key Guideline Recommendations for Hormone Receptor-Positive MBC

ASCO Key Guideline Recommendations for Hormone Receptor-Positive MBC (cont)

Endocrine Trials in First-Line MBC

Emerging Therapies for Hormone Receptor-Positive Breast Cancer

FALCON Anastrozole vs Fulvestrant in Hormone Receptor-Positive Advanced or MBC

FALCON Results

PALOMA-1 Palbociclib Plus Letrozole vs Letrozole Alone

PALOMA-1 Results

PALOMA-2 Palbociclib Plus Letrozole vs Letrozole Alone

PALOMA-2 Results

PALOMA-2 AE Summary

MONALEESA-2 Ribociclib Plus Letrozole vs Letrozole in Hormone Receptor-Positive Advanced Breast Cancer

MONALEESA-2 Results

MONALEESA-2 Safety Profile

Case Study 2

Case Study 2 (cont)

Options for Patients Who Have Disease Progression During/After Endocrine Therapy

PALOMA-3 Fulvestrant ± Palbociclib

PALOMA-3 Results

ESR1 Mutations

ESR1 Mutations Results

MONARCH 1 Abemaciclib

MONARCH1 Results

neoMONARCH Neoadjuvant Phase 2 Trial Interim Analysis

neoMONARCH Ki67 Results

Neoadjuvant Palbociclib With Anaztrozole

BOLERO-2 Everolimus Plus Exemestane vs Placebo Plus Exemestane

BOLERO-2 Results

SWISH Trial: Dexamethasone-Based Mouthwash for Stomatitis

Emerging Strategies

Conclusions

Abbreviations

Abbreviations (cont)

Abbreviations (cont)